Factors associated with acute kidney injury in rhabdomyolysis: Insights from a prospective study

Table 5 Medical management and intensive care unit stay-related complications of patients with rhabdomyolysis: Comparison between those who developed acute kidney injury and those who did not, n (%)

Variables	All patients (n = 54)	Non-AKI group (n = 26)	AKI group (n = 28)	P value
Hydration	48 (88.9)	26 (100)	22 (78.6)	0.012
Infection	38 (70.4)	15 (57.7)	23 (82.1)	0.049
Antibiotics	40 (74.1)	17 (65.4)	21 (75)	0.439
Amoxicillin-clavulanic acid	19 (35.2)	11 (42.3)	8 (28.6)	0.352
Piperacillin/tazobactam	17 (31.5)	9 (34.6)	8 (28.6)	0.753
Cefazolin	2 (3.7)	0 (0)	2 (7.1)	0.244
Cefotaxime	7 (13)	1 (3.8)	6 (21.4)	0.053
Imipenem	13 (24.1)	3 (11.5)	10 (35.7)	0.034
Gentamicin	4 (7.4)	1 (3.8)	3 (10.7)	0.606
Amikacin	17 (31.5)	10 (38.5)	7 (25)	0.242
Vancomycin	1 (1.9)	0 (0)	1 (3.6)	0.523
Teicoplanin	5 (9.3)	1 (3.8)	4 (14.3)	0.202
Metronidazole	3 (5.6)	1 (3.8)	2 (7.1)	0.535
Colistin	5 (9.3)	0 (0)	5 (17.9)	0.023
Fluoroquinolone	4 (7.4)	1 (3.8)	3 (10.7)	0.303
Quinolone	2 (3.7)	0 (0)	2 (7.1)	0.267
States of shock	17 (31.5)	7 (26.9)	10 (35.7)	0.487
Contrast agent use	35 (64.8)	12 (46.2)	23 (82.1)	0.006

AKI: Acute kidney injury.